Assessment of Multimorbidity in Patients with COVID-19 and Polymorphisms C807T of the ITGA2 Gene and T1565C of the ITGB3 Gene

Introduction. ITGA2 gene C807T and ITGB3 gene T1565C polymorphisms influence the development of cardiovascular conditions and may worsen the condition of patients with COVID-19. The aim of this study was to evaluate the multimorbidity in COVID-19 patients with ITGA2 gene C807T and ITGB3 gene T1565C polymorphisms. Materials and methods . The case-control study was conducted: group 1 included 25 patients with COVID-19; group 2 — 25 patients with COVID-19 and acute coronary syndrome. The groups were adjusted by age, volume of lung lesions, body mass index, terms of hospital stay. The genetic study was performed on a DTprime (DT-96) detection amplifier. Results. In Group 1, chronic heart failure occurred in 6 CC patients of ITGA2 gene, 8 — with T allele; in Group 2 — 12 and 7 patients, respectively ( p = 0.036). Previous acute myocardial infarction occurred in 1 CC patient, no persons with T allele; in Group 2 — 2 and 9 cases, respectively ( p < 0.001). In Group 1, obesity occurred in 8 CC patients, 1 — with T allele; in Group 2 — 7 and 3 cases, respectively ( p = 0.006). The ITGB3 gene polymorphism had no effect on the multimorbidity. Discussion . There is a close connection between the ITGA2 (C807T) polymorphism and the development of recurrent myocardial infarction and chronic heart failure against the background of the existing systemic inflammatory process, platelet hyperactivation and fibrosis. Conclusion. The data obtained indicate a significant influence of ITGA2 (C807T) gene polymorphism and the absence of an influence of ITGB3 (T1565C) gene polymorphism on the multimorbidity of patients with COVID-19.